% | $
Quotes you view appear here for quick access.

Medical Marijuana, Inc. Message Board

  • diamondsgold939 diamondsgold939 Nov 21, 2012 6:42 PM Flag

    MJNA with CanChew Biotechnologies

    CanChew Biotechnologies is conducting a Market Trial of its hemp based CBD chewing gum. For a limited time participants can received up to 2 months of CanChew's hemp based CBD gum for free, they need only pay for shipping. To be included in the market trial potential participants will need to register at CanChew's website and then complete the application.

    CanChew Biotech focuses on the treatment of pain and other medical disorders with the application of chewing gum based cannabis/cannabinoids medical products. The company targets research and execution of their clinical development plan and subsequently out licensing of their technology. The development focuses on the R&D of the formulation, production and the development of chewing gum based products in their respective fields e.g: for the treatment of numerous diseases like pain, nausea and vomiting, anorexia, spasticity and various other symptoms.
    Product Development

    CanChew Biotech has a patented technology which comprises the inclusion of regulatory acceptable active pharmaceutical ingredients [API] of the cannabinoid variety in a patented and proprietary chewing gum delivery formulation. CanChew® for medical purposes, specifically pain treatment associated with a variety of long term, chronic or degenerative diseases whereby cannabinoid therapy is finding increasing application in a global marketplace.
    CanChew Advantage

    The CanChew® formulation offers a unique, socially acceptable, patient friendly, taste masked and convenient delivery format for delivery of the cannabis/cannabinoid(s) based medicine via the oral mucosal membranes.

    CanChew's full oral-oropharyngeal mucous membrane delivery method is superior to other delivery methods.

    Advantages of Oral Mucosal Drug Delivery system:

    Bypass of the gastrointestinal tract and hepatic portal system, increasing the bioavailability of orally administered drugs that otherwise undergo hepatic first-pass metabolism.
    Drug is protected from degradation due to pH and digestive enzymes of the middle gastrointestinal tract.
    Improved patient compliance due to the elimination of associated pain with injections.
    Sustained drug delivery.
    A relatively rapid onset of action can be achieved relative to the oral route.
    Oral mucosal systems exhibit a faster initiation and decline of delivery than do transdermal patches.
    The large contact surface of the oral cavity contributes to rapid and extensive drug absorption.

    Sentiment: Strong Buy

0.0484+0.0001(+0.21%)Aug 26 3:57 PMEDT